Matches in SemOpenAlex for { <https://semopenalex.org/work/W3155289023> ?p ?o ?g. }
- W3155289023 endingPage "1795" @default.
- W3155289023 startingPage "1795" @default.
- W3155289023 abstract "Glioblastoma (GBM), the most frequent and aggressive glial tumor, is currently treated as first line by the Stupp protocol, which combines, after surgery, radiotherapy and chemotherapy. For recurrent GBM, in absence of standard treatment or available clinical trials, various protocols including cytotoxic drugs and/or bevacizumab are currently applied. Despite these heavy treatments, the mean overall survival of patients is under 18 months. Many clinical studies are underway. Based on clinicaltrials.org and conducted up to 1 April 2020, this review lists, not only main, but all targeted therapies in phases II-IV of 257 clinical trials on adults with newly diagnosed or recurrent GBMs for the last twenty years. It does not involve targeted immunotherapies and therapies targeting tumor cell metabolism, that are well documented in other reviews. Without surprise, the most frequently reported drugs are those targeting (i) EGFR (40 clinical trials), and more generally tyrosine kinase receptors (85 clinical trials) and (ii) VEGF/VEGFR (75 clinical trials of which 53 involving bevacizumab). But many other targets and drugs are of interest. They are all listed and thoroughly described, on an one-on-one basis, in four sections related to targeting (i) GBM stem cells and stem cell pathways, (ii) the growth autonomy and migration, (iii) the cell cycle and the escape to cell death, (iv) and angiogenesis." @default.
- W3155289023 created "2021-04-26" @default.
- W3155289023 creator A5005594936 @default.
- W3155289023 creator A5020320735 @default.
- W3155289023 creator A5045699583 @default.
- W3155289023 creator A5080479183 @default.
- W3155289023 creator A5085792385 @default.
- W3155289023 date "2021-04-09" @default.
- W3155289023 modified "2023-10-09" @default.
- W3155289023 title "A Systematic Review of Glioblastoma-Targeted Therapies in Phases II, III, IV Clinical Trials" @default.
- W3155289023 cites W1131650172 @default.
- W3155289023 cites W1500946936 @default.
- W3155289023 cites W1530069278 @default.
- W3155289023 cites W1542183320 @default.
- W3155289023 cites W1638095649 @default.
- W3155289023 cites W164445532 @default.
- W3155289023 cites W1650741782 @default.
- W3155289023 cites W1770392775 @default.
- W3155289023 cites W1879220818 @default.
- W3155289023 cites W1881534971 @default.
- W3155289023 cites W1887747927 @default.
- W3155289023 cites W1912887175 @default.
- W3155289023 cites W1932563524 @default.
- W3155289023 cites W1965157625 @default.
- W3155289023 cites W1965415098 @default.
- W3155289023 cites W1966325786 @default.
- W3155289023 cites W1966743152 @default.
- W3155289023 cites W1967142209 @default.
- W3155289023 cites W1967180587 @default.
- W3155289023 cites W1967894078 @default.
- W3155289023 cites W1969317010 @default.
- W3155289023 cites W1971343062 @default.
- W3155289023 cites W1971418893 @default.
- W3155289023 cites W1971495943 @default.
- W3155289023 cites W1972700706 @default.
- W3155289023 cites W1975365481 @default.
- W3155289023 cites W1976881265 @default.
- W3155289023 cites W1979561126 @default.
- W3155289023 cites W1982236564 @default.
- W3155289023 cites W1983660153 @default.
- W3155289023 cites W1983726466 @default.
- W3155289023 cites W1987187902 @default.
- W3155289023 cites W1987681742 @default.
- W3155289023 cites W1988726305 @default.
- W3155289023 cites W1989072865 @default.
- W3155289023 cites W1990289715 @default.
- W3155289023 cites W1990763008 @default.
- W3155289023 cites W1992868626 @default.
- W3155289023 cites W1995327201 @default.
- W3155289023 cites W1997304999 @default.
- W3155289023 cites W1999920903 @default.
- W3155289023 cites W2000723196 @default.
- W3155289023 cites W2002398236 @default.
- W3155289023 cites W2003727692 @default.
- W3155289023 cites W2003976380 @default.
- W3155289023 cites W2004432187 @default.
- W3155289023 cites W2005436740 @default.
- W3155289023 cites W2007649418 @default.
- W3155289023 cites W2008628163 @default.
- W3155289023 cites W2012562754 @default.
- W3155289023 cites W2015642017 @default.
- W3155289023 cites W2015660037 @default.
- W3155289023 cites W2015737413 @default.
- W3155289023 cites W2017917846 @default.
- W3155289023 cites W2018049759 @default.
- W3155289023 cites W2018101957 @default.
- W3155289023 cites W2019414065 @default.
- W3155289023 cites W2020304503 @default.
- W3155289023 cites W2020486016 @default.
- W3155289023 cites W2024672608 @default.
- W3155289023 cites W2025372894 @default.
- W3155289023 cites W2026905829 @default.
- W3155289023 cites W2027147390 @default.
- W3155289023 cites W2030501835 @default.
- W3155289023 cites W2032690575 @default.
- W3155289023 cites W2033279684 @default.
- W3155289023 cites W2036063985 @default.
- W3155289023 cites W2036388175 @default.
- W3155289023 cites W2036562916 @default.
- W3155289023 cites W2036586511 @default.
- W3155289023 cites W2038657036 @default.
- W3155289023 cites W2039275948 @default.
- W3155289023 cites W2040176056 @default.
- W3155289023 cites W2044108812 @default.
- W3155289023 cites W2047138539 @default.
- W3155289023 cites W2048182455 @default.
- W3155289023 cites W2049315573 @default.
- W3155289023 cites W2052630543 @default.
- W3155289023 cites W2054323740 @default.
- W3155289023 cites W2054455334 @default.
- W3155289023 cites W2055532721 @default.
- W3155289023 cites W2061288640 @default.
- W3155289023 cites W2061345986 @default.
- W3155289023 cites W2062110561 @default.
- W3155289023 cites W2064076634 @default.
- W3155289023 cites W2066740999 @default.
- W3155289023 cites W2067561733 @default.
- W3155289023 cites W2069377117 @default.